# Nuclide record nct03972657 (trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/trials/nct03972657/>
  a schema:MedicalTrial ;
  nuclide:kind "trial" ;
  schema:identifier "nct03972657", "NCT03972657" ;
  schema:name "A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metasta"@en ;
  schema:description "A phase 1/2 trial of Cemiplimab in prostate cancer and renal cell carcinoma, run by Regeneron Pharmaceuticals, now recruiting."@en ;
  schema:url <https://nuclide.cc/trials/nct03972657/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03972657> ;
  nuclide:status "recruiting" ;
  nuclide:tag "ctgov-ingest" ;
  nuclide:phase "1/2" ;
  nuclide:indications <https://nuclide.cc/indications/prostate/>, <https://nuclide.cc/indications/rcc/>, <https://nuclide.cc/indications/prostate-mcrpc/> .